环丁腈 | 4426-11-3

• 物质功能分类: 有机原料 - 腈类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 环丁腈
• 中文别名: 环丁烷甲腈；氰基环丁烷；环丁基腈
• 英文名称: cyclobutanecarbonitrile
• 英文别名: cyclobutylnitrile
• CAS: 4426-11-3
• 化学式: C₅H₇N
• mdl: MFCD00013735
• 分子量: 81.1173
• InChiKey: GFBLFDSCAKHHGX-UHFFFAOYSA-N

物化性质

• 沸点：
  144-146°C
• 密度：
  0,868 g/cm3
• 闪点：
  42°C
• 稳定性/保质期：

  常温常压下稳定，无色纯净的液体。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  6.1
• 危险品标志：
  T
• 安全说明：
  S16,S3/7,S36/37/39,S9
• 危险类别码：
  R20/21/22,R10
• 危险品运输编号：
  3275
• 海关编码：
  2926909090
• 危险类别：
  6.1
• 包装等级：
  II
• WGK Germany：
  3
• 储存条件：
  请将药品存放在避光、通风干燥的地方，并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Cyclobutanecarbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H331: Toxic if inhaled
H302: Harmful if swallowed
H312: Harmful in contact with skin
H226: Flammable liquid and vapour
Keep away from heat/sparks/open flames/hot surfaces. No smoking
P210:
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P303+P361+P353: IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: Cyclobutanecarbonitrile
CAS number: 4426-11-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H7N
Molecular weight: 81.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN1992 Class: 3 Packing group: III
Proper shipping name: FLAMMABLE LIQUIDS, TOXIC, N.O.S. (Cyclobutanecarbonitrile)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：无色且纯净的液态物质。

反应信息

• 作为反应物：
  描述：

  环丁腈 在 三氯化磷 作用下， 生成 环丁基甲酰氯
  参考文献：
  名称：

  Freund; Gudeman, Chemische Berichte, 1888, vol. 21, p. 2697

  摘要：

  DOI：
• 作为产物：
  描述：

  5-溴戊腈 在 氧气 、 高氯酸四乙基铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以72%的产率得到环丁腈
  参考文献：
  名称：

  Carelli, Italo; Curulli, Antonella; Inesi, Achille, Journal of Chemical Research, Miniprint, 1989, # 11, p. 2554 - 2571

  摘要：

  DOI：

文献信息

• [EN] BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BIARYLAMIDE DE PRODUCTION DE LEUKOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012082817A1

  公开（公告）日：2012-06-21

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中A、B、C、R1a、R1b、R2、R3、R4a和R4b如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• Parallel Synthesis of 1<i>H-</i>Pyrazolo[3,4-<i>d</i>]pyrimidines via Condensation of <i>N</i>-Pyrazolylamides and Nitriles
  作者：Akshay A. Shah、Lois K. Chenard、Joseph W. Tucker、Christopher J. Helal

  DOI：10.1021/acscombsci.7b00116

  日期：2017.11.13

  A novel parallel medicinal chemistry (PMC)-enabled synthesis of 1H-pyrazolo[3,4-d]pyrimidines employing condensation of easily accessible N-pyrazolylamides and nitriles has been developed. The presented studies describe singleton and library enablements that allowed rapid generation of molecular diversity to examine C4 and C6 vectors. This chemistry enabled access to challenging alkyl substituents

  已开发出一种新颖的平行药物化学（PMC）合成1 H-吡唑并[3,4- d ]嘧啶的方法，该方法采用易于获得的N-吡唑烷基酰胺和腈的缩合反应。提出的研究描述了单例和库使能，其允许快速产生分子多样性来检查C4和C6载体。这种化学性质使人们能够使用具有挑战性的烷基取代基，从而扩大了整个化学空间，使其超过了典型的C（sp 2）–C（sp 2）偶联和S N Ar转化所能提供的空间。此外，讨论了允许使用更大和更多样化的酰胺和羧酸作为腈前体的单体基团互变。
• [EN] DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES<br/>[FR] DÉRIVÉS D'AMIDES D'ACIDE 6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-CARBOXYLIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010141273A1

  公开（公告）日：2010-12-09

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-a]咪唑-3-羧酸酰胺的衍生物对CAMs和白细胞整合素的相互作用具有良好的抑制作用，因此在炎症性疾病的治疗中很有用。
• [EN] BENZIMIDAZOLE ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX À BASE DE BENZIMIDAZOLE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011097491A1

  公开（公告）日：2011-08-11

  Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是公式(I)和(II)的化合物以及它们的药用可接受盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒家族成员如丙型肝炎病毒（HCV）介导的病毒感染。
• SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20180305320A1

  公开（公告）日：2018-10-25

  The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

  本发明涉及式I化合物：以及药用可接受的盐。此类化合物可用于治疗RORgammaT介导的疾病或状况。

表征谱图